We recently received an e-mail from Richway International (the BioMat’s parent company) about copycat versions of the original BioMat. We share the e-mail content here:
“In recent times, we have noticed a concerning trend where copycat companies have chosen to prioritize cost-cutting measures over the development and manufacturing of high-quality products with established therapeutic efficacy.
Instead of investing in advanced technology and research, these companies seem to focus their efforts on marketing low-cost alternatives that pose grave risks to you, the customer, and your well-being.
What concerns us most is the use of substandard components by these copycat companies, including thin, low-quality plastic for their heating elements. This careless approach raises significant safety concerns, and we fear that a major safety incident may be just around the corner.
As a responsible and proactive measure, we are strongly urging these bio-mat copycat companies to, at the very least, pursue minimal electrical safety certifications such as UL or CSA, even if full compliance with all U.S. medical device regulations proves challenging and costly. Acquiring these certifications represents a fundamental safety step to prevent potential accidents and safeguard the customers’ health.
In the United States and Canada, selling far-infrared thermal devices necessitates a multitude of safety certifications, including:
- Good Manufacturing Practices (GMP)
- Federal Communications Commission (FCC)
- Electromagnetic safety certifications (FC)
- National Recognized Testing Laboratory (NRTL) electrical safety certifications (UL, CSA, ETR)
- Plus several others that are less recognizable from a consumer standpoint.
These certifications are vital prerequisites for importing medical devices into the United States, yet many BioMat copycat companies continue to import and sell their products without obtaining any certifications.
We share this information with you to ensure you are informed about these critical concerns.”
If you have questions about anything mentioned in this blog post, please reach out to us for further discussion at [email protected].
